Establishing an anemia clinic for optimal erythropoietic-stimulating agent use in hematology-oncology patients

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 6, Issue 6, 2008, Pages 577-584

  Gilreath, Jeffrey A ^a,b   Sageser, Daniel S ^a,b   Jorgenson, James A ^a,c   Rodgers, George M ^a,d  

^a University of Utah Hospitals and Clinics ^*

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH HOSPITAL   (United States)

^d UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Algorithm; Anemia; Cancer; Chemotherapy; Clinic; Erythropoietic stimulating agent

Indexed keywords

CYANOCOBALAMIN; DIPHENHYDRAMINE; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FOLIC ACID; IRON; IRON DEXTRAN; METHYLPREDNISOLONE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARACETAMOL; RECOMBINANT ERYTHROPOIETIN;

ALGORITHM; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; CYANOCOBALAMIN DEFICIENCY; DRUG DOSE INCREASE; FOLIC ACID DEFICIENCY; HUMAN; INTERMETHOD COMPARISON; IRON DEFICIENCY ANEMIA; IRON STORAGE; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHARMACIST; PRACTICE GUIDELINE; REIMBURSEMENT; TREATMENT OUTCOME;

EID: 47549091360     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2008.0044     Document Type: Article

References (44)

1. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer in Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-2306.
2. Rodgers CM, Becker PS, Bennett CL, et al. NCCN Clinical Practice Guidelines in Oncology: Cancer- and Treatment-Related Anemia, version 2.2008. Available at: http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf. Accessed April 11, 2008.
3. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301-1307.
4. Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12:231-242.
5. Brugnara C, Colella GM, Cremins JC, et al. Effects of subcutaneous recombinant human erythropoietin in normal subjects: development of decreased reticulocyte hemoglobin content and iron-deficient erythropoiesis. J Lab Clin Med 1994;123:660-667.
6. Bamgbola OF, Kaskel F. Role of folate deficiency on erythropoietin resistance in pediatric and adolescent patients on chronic dialysis. Pediatr Nephrol 2005;20:1622-1629.
7. Breen CP, Macdougall IC. Correction of epoetin-resistant mega-loblastic anaemia following vitamin B12 and folate administration. Nephron 1999;83:374-375.
8. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
9. Schwartzberg LS, Yee LK, Senecal FM, et al. A randomized comparison of every-2-week Darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 2004;9:696-707.
10. Procrit [package insert]. Raritan, NJ: Ortho Biotech Products, L.P.; 2005.
11. Aranesp [package insert]. Thousand Oaks, CA: Amgen Inc.; 2006.
12. Hedenus M, Birgegård G, Näsman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007;21:627-632.
13. Bastit L, Vandebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008;26:1611-1608.
14. Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008;26:1619-1625.
15. Auerbach M, Henry DH. Increased importance of intravenous iron in chemotherapy-induced anemia. J Clin Oncol 2007;25:2145-2146.
16. Premier's Perspective Comparative Database [database online]. Charlotte, NC: Premier Inc.
17. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-460.
18. Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
19. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25:1027-1032.
20. Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403.
21. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-924.
22. Wilkinson J. Describing the usage patterns and outcomes of hematopoietic agents at the Huntsman Cancer Institute. Presented at the Western States Residency Conference; May 2004; Asilomar, CA.
23. Kuo GM, Buckley TE, Fitzsimmons DS, Steinbauer JR. Collaborative drug therapy management services and reimbursement in a family medicine clinic. Am J Health Syst Pharm 2004;61:343-354.
24. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):204S-233S.
25. Gray DR, Garabedian-Ruffalo SM, Chretien SD. Cost-justification in a clinical pharmacist-managed anticoagulation clinic. Ann Pharmacother 2007;41:496-501.
26. Adamson R, Baribeault D, Griffith N, et al. Contemporary growth factor management: three institutional perspectives. Therapeutic Insights and Review 2006;41(Suppl 1):1-14.
27. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy of epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice: Procrit Study Group. J Clin Oncol 1997;15:1218.
28. Cella D. The Functional Assessment of Cancer Therapy - Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34(Suppl 2):13-19.
29. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634.
30. Lee M. Basic Skills in Interpreting Laboratory Data. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2004.
31. Beutler E, Hoffbrand AV, Cook JD. Iron deficiency and overload. Hematology 2003;1:40-61.
32. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006;47(5 Suppl 3):S11-145.
33. INFeD [package insert]. Morristown, NJ: Watson Pharmaceuticals, Inc.; 2001.
34. Anuradha S, Singh NP, Agarwal SK. Total dose infusion iron dextran therapy in predialysis chronic renal failure patients. Ren Fail 2002;3:307-313.
35. Auerbach M, Chaudry M, Goldman H, et al. Value of methylprednisolone in prevention of arthralgia-myalgia syndrome associated with total dose infusion of iron dextran: a double-blind, randomized trial. J Lab Clin Med 1998;131:257-260.
36. Ferrlecit [package insert]. Florham Park, NJ: Schein Pharmaceuticals, Inc.; 2001.
37. Venofer [package insert]. Shirley, NY: American Regent Laboratories, Inc.; 2001.
38. Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kid Dis 2001;38:988-991.
39. Deicher R, Ziai F, Cohen G, et al. High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int 2003;64:728-736.
40. Silverstein SB, Rodgers GM. Parenteral iron therapy options. Am J Hem 2004;76:74-78.
41. Folk acid tablets USP 1 mg [package insert]. Corona, CA: Watson Laboratories, Inc.; 2005.
42. Schiffl H, Lang S. Folic acid deficiency modifies the haematopoietic response to recombinant human erythropoietin in maintenance dialysis patients. Nephrol Dial Transplant 2006;21:133-137.
43. Breen CP, Macdougall IC. Correction of epoetin-resistant mega-loblastic anaemia following vitamin B12 and folate administration. Nephron 1999;83:374-375.
44. Kuzminski AM, Del Giacco EJ, Allen RH, et al. Effective treatment of cobalamin deficiency with oral cobalamin. Blood 1998;92:1191-1198.